Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J.I. Na
P1.09-12 Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients With NSCLC Highlights Correlation of ROS1 and PD-L1 Expression
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.17-01 PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients From Brazil
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.09-06 the Incidence of PD-L1 in NSCLC and Its Correlation With Driver Mutations in Turkish Patients; A Single Center Experience
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
ROS1 Rearrangements Are Only Found in Lung Adenocarcinomas With Diffuse Strong IHC Expression of ROS1
Pathology
Forensic Medicine
Pathology
Ceritinib Beim ROS1-positiven NSCLC
Im Focus Onkologie
P2.09-13 Correlation of ROS1 (SP384) Immunohistochemistry With ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer
Oncology in Clinical Practice
Oncology